Rodman & Renshaw reiterated its Market Outperform rating on Adventrx Pharmaceuticals ANX. At the same time, the rating agency reduced its price target on the company's stock from $16 to $9. On Wednesday, ANX had a disastrous session, losing 58.28% of its value to end the day at $1.06. Its shares started to rebound in today's pre-market trading, rising 2.83% to stand around $1.09.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in